龙8娱乐

当前位置: 首页 > 药学版 > 药品研究 > 药理药效学 > 正文
编号:10566753
Randomized clinical trial of an implantable drug delivery system compared with c
http://www.100md.com
     PURPOSE: Implantable intrathecal drug delivery systems (IDDSs) have been used to manage refractory cancer pain, but there are no randomized clinical trial (RCT) data comparing them with comprehensive medical management (CMM). PATIENTS AND METHODS: We enrolled 202 patients on an RCT of CMM versus IDDS plus CMM. Entry criteria included unrelieved pain (visual analog scale [VAS] pain scores >/= 5 on a 0 to 10 scale). Clinical success was defined as >/= 20% reduction in VAS scores, or equal scores with >/= 20% reduction in toxicity. The main outcome measure was pain control combined with change of toxicity, as measured by the National Cancer Institute Common Toxicity Criteria, 4 weeks after randomization. RESULTS: Sixty of 71 IDDS patients (84.5%) achieved clinical success compared with 51 of 72 CMM patients (70.8%, P =.05). IDDS patients more often achieved >/= 20% reduction in both pain VAS and toxicity (57.7% [41 of 71] v 37.5% [27 of 72], P =.02). The mean CMM VAS score fell from 7.81 to 4.76 (39% reduction); for the IDDS group, the scores fell from 7.57 to 3.67 (52% reduction, P =.055). The mean CMM toxicity scores fell from 6.36 to 5.27 (17% reduction); for the IDDS group, the toxicity scores fell from 7.22 to 3.59 (50% reduction, P =.004). The IDDS group had significant reductions in fatigue and depressed level of consciousness (P
龙8娱乐qy8千亿国际欢迎您qy8千亿国际亚虎娱乐老虎机
亚虎娱乐老虎机龙8娱乐老虎机梦之城娱乐梦之城娱乐
亚虎娱乐老虎机qy8千亿国际欢迎您qy8千亿国际龙8娱乐官网
龙8娱乐龙8娱乐城开户送8 88龙8娱乐老虎机亚虎娱乐老虎机
亚虎娱乐老虎机龙8娱乐老虎机梦之城娱乐梦之城娱乐